The spectrum of scleroderma lung disease

被引：33

作者：

Highland, Kristin B.

Garin, Margaret C.

Brown, Kevin K.

机构：

[1] Med Univ S Carolina, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA

[2] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Natl Jewish Med & Res Ctr, Dept Med, Interstitial Lung Dis Program, Denver, CO USA

来源：

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE | 2007年 / 28卷 / 04期

关键词：

scleroderma; systemic sclerosis; interstitial lung disease; pulmonary arterial hypertension;

D O I：

10.1055/s-2007-985613

中图分类号：

R4 [临床医学];

学科分类号：

1002 [临床医学]; 100602 [中西医结合临床];

摘要：

Pulmonary disease is the most common cause of death in patients with systemic sclerosis. This article discusses the variety of ways the lung is affected in systemic sclerosis. These include pulmonary hypertension, interstitial lung disease and other restrictive disorders, obstructive disease, pleural disease, lung cancer, and aspiration. For each manifestation we outline the current knowledge of etiology, risk factors, diagnosis, treatment, and prognosis. We also discuss the current state of lung transplantation in this population.

引用

页码：418 / 429

页数：12

共 130 条

[1]

LUNG-FUNCTION ABNORMALITIES AND DECLINE OF SPIROMETRY IN SCLERODERMA - AN OVERRATED DANGER [J].

ABRAMSON, MJ ;

BARNETT, AJ ;

LITTLEJOHN, GO ;

SMITH, MM ;

HALL, S .

POSTGRADUATE MEDICAL JOURNAL, 1991, 67 (789) :632-637

[2]

Airò P, 2004, CLIN EXP RHEUMATOL, V22, P573

[3]

IMPROVED PULMONARY-FUNCTION IN SYSTEMIC-SCLEROSIS AFTER TREATMENT WITH CYCLOPHOSPHAMIDE [J].

AKESSON, A ;

SCHEJA, A ;

LUNDIN, A ;

WOLLHEIM, FA .

ARTHRITIS AND RHEUMATISM, 1994, 37 (05) :729-735

[4]

Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma [J].

Alkotob, M. Luay ;

Soltani, Peyman ;

Sheatt, Mohammad A. ;

Katsetos, Manny C. ;

Rothfield, Naomi ;

Hager, W. David ;

Foley, Raymond J. ;

Silverman, David I. .

CHEST, 2006, 130 (01) :176-181

[5]

ACUTE AND LONG-TERM EFFECTS OF NIFEDIPINE ON PULMONARY AND SYSTEMIC HEMODYNAMICS IN PATIENTS WITH PULMONARY-HYPERTENSION ASSOCIATED WITH DIFFUSE SYSTEMIC-SCLEROSIS, THE CREST SYNDROME AND MIXED CONNECTIVE-TISSUE DISEASE [J].

ALPERT, MA ;

PRESSLY, TA ;

MUKERJI, V ;

LAMBERT, CR ;

MUKERJI, B ;

PANAYIOTOU, H ;

SHARP, GC .

AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (17) :1687-1691

[6]

Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis [J].

Apras, S ;

Ertenli, I ;

Ozbalkan, Z ;

Kiraz, S ;

Ozturk, MA ;

Haznedaroglu, IC ;

Çobankara, V ;

Pay, S ;

Calguneri, M .

ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2256-2261

[7]

Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease [J].

Arcasoy, SM ;

Christie, JD ;

Ferrari, VA ;

Sutton, MS ;

Zisman, DA ;

Blumenthal, NP ;

Pochettino, A ;

Kotloff, RM .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) :735-740

[8]

Assous N, 2005, CLIN EXP RHEUMATOL, V23, P199

[9]

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[10]

Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].

Badesch, DB ;

Abman, SH ;

Ahearn, GS ;

Barst, RJ ;

McCrory, DC ;

Simonneau, G ;

McLaughlin, VV .

CHEST, 2004, 126 (01) :35S-62S

← 1 2 3 4 5 6 7 8 9 10 →